Potential Targets for the Development of Novel Antidepressants: Future Perspectives

Author(s): Vishnu N. Thakare, Bhoomika M. Patel.

Journal Name: CNS & Neurological Disorders - Drug Targets

Volume 14 , Issue 2 , 2015

Become EABM
Become Reviewer

Abstract:

Depression is an affective disorder characterized by hallucination, delusion and increased social risk and is estimated to affect approximately 20 % of the population at some point during the lifetime. As per World Health Organization (WHO) it is predicted to be the leading cause of burden of disease by 2030. Effects of currently available antidepressants have explained the monoamine hypothesis of depression, which proposes that impaired release of serotonin, noradrenaline and dopamine, are thought to be responsible for the development of depressive symptoms. However, these drugs are not specific for their action, as they also inhibit other enzymes; this explains the side effects/drug interactions associated with these agents. The present review will familiarize the readers with novel targets being identified for depression which will be certainly beneficial for researcher, academician for the development of drugs for the management of depression and related behavior.

Keywords: Cholinergic receptors, cocaine and amphetamine regulated transcript peptide, depression, histaminergic receptors, N-methyl-D-aspartate, oxidative stress, substance P.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 14
ISSUE: 2
Year: 2015
Page: [270 - 281]
Pages: 12
DOI: 10.2174/1871527313666140806121648
Price: $58

Article Metrics

PDF: 25